That is the one! That is the counter example to EXEL. I forgot their name. They are the example of promising, too good to be true phase III results from post hac analysis, good enough to obtain a special and abbreviated FDA protocol, only to see such data, that looked amazing, to collapse when put into a randomized trial with pre-determined end points.
YMI is my cautionary cancer drug company. They are still at it. Maybe they will get one this time.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.